Precigen Inc PGEN
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-08-08 |
| Shares Out. | 356,510,000 |
| Website | precigen.com/ ↗ |
| Phone | 13015569900 |
| Employees | 47 |
| Revenue | $23.3M |
| Gross Profit | $20.7M |
| Net Income | -$7.9M |
| Free Cash Flow | -$117.0M |
| Total Assets | $138.6M |
| Total Liabilities | $118.4M |
| Equity | $20.2M |
About Precigen Inc
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Precigen Inc is a publicly traded company under the ticker symbol PGEN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)